KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo (pbo) plus pem and platinum for metastatic nonsquamous NSCLC
Annals of Oncology(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Annals of Oncology(2022)